EMulate Therapeutics Announces the Publication of Its Phase I/II Results in CNS Oncology: “An Expanded Safety/Feasibility Study of the EMulate Therapeutics Voyager in Patients with Recurrent GBM”

Written By Kyle Kingma
Kyle Kingma
Previous

Society for Neuro-Oncology Abstract
Next

EMulate Therapeutics Announces Brett Greene, Veteran in the Psychedelic and Cannabinoid Biotechnology Industry, as a Company Advisor